Investors focused on the Medical space have likely heard of Mallinckrodt public limited (NYSE:MNK), but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Mallinckrodt public limited is a member of our Medical group, which includes 850 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. MNK is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for MNK's full-year earnings has moved 10.30% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, MNK has returned 48.61% so far this year. Meanwhile, stocks in the Medical group have gained about 10.03% on average. As we can see, Mallinckrodt public limited is performing better than its sector in the calendar year.
To break things down more, MNK belongs to the Medical - Generic Drugs industry, a group that includes 23 individual companies and currently sits at #109 in the Zacks Industry Rank. On average, this group has gained an average of 10.91% so far this year, meaning that MNK is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to MNK as it looks to continue its solid performance.
Mallinckrodt public limited company (MNK): Free Stock Analysis Report
Original post